Skip to main content

Table 3 Anticoagulant treatments and genes with variants that potentially affect drug response

From: Application of personalized medicine to chronic disease: a feasibility assessment

Drug name Brand name Pharmacogenetic genes PubMed ID reference Details
Warfarin Coumadin CYP2C9; VKORC1; CALU; CACNA1C; CYP4F2 20200517; Risk or phenotype-associated alleles. Weekly warfarin dose requirements were lower in those with CYP2C9 loss-of-function alleles as compared with the wild type CYP2C9 genotype
19794411;
20072124;
17341693;
18250228;
20203262;
18535201;
19297519;
19300499;
18535201
Dabigatran* Pradax   
Heparin    
Enoxaparin Lovenox    
  1. *Dabigatran is not on Ontario or BC formularies, but is used in Canada.